Antibody Drug Conjugates: windows of opportunity

04th July 2023

Antibody Drug Conjugates (ADCs) are continuing to improve patient outcomes. Dr Petra Dieterich, Dr Ian Glassford and Dr Jeff Mocny, sat down with Drug Target Review to discuss real-world data that is challenging traditional scientific thinking in the ADC therapeutic space when it comes to drug development.

Read more to gain an understanding of the ADC therapeutic window, and the need for further data to improve our understanding and how to refine drug design for these types of programs with safety